Skip to content
10-Q

Quarterly Report

TherapeuticsMD, Inc. TXMD

0001213900-25-042697

← back to feed
Filed
May 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 11, 2025 11.57M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $5.75M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $5.06M
Current Liabilities Q1 2025 · Mar 31, 2025 $4.74M
Current Liabilities Q1 2025 · Dec 31, 2024 $5.17M
Total Liabilities Q1 2025 · Mar 31, 2025 $11.5M
Total Liabilities Q1 2025 · Dec 31, 2024 $11.45M
Current Assets Q1 2025 · Mar 31, 2025 $12.51M
Current Assets Q1 2025 · Dec 31, 2024 $12.26M
Total Assets Q1 2025 · Mar 31, 2025 $38.24M
Total Assets Q1 2025 · Dec 31, 2024 $38.82M
Sga Expense Q1 2025 · Mar 31, 2025 $1.08M
Sga Expense Q1 2025 · Mar 31, 2024 $1.32M
Shares Diluted Q1 2025 · Mar 31, 2024 11.53M sh
Stockholders Equity Q1 2025 · Mar 31, 2024 $28.66M
Stockholders Equity Q1 2025 · Dec 31, 2023 $29.29M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.06
Eps Basic Q1 2025 · Mar 31, 2024 −$0.06
Net Income Q1 2025 · Mar 31, 2024 −$734K
Operating Income Q1 2025 · Mar 31, 2024 −$1.14M